ImmunoCellular Therapeutics receives access to BioWa POTELLIGENT Technology
Under the agreement, Biowa will receive the right to certain antibody technology from IMUC and selected option rights to IMUC antibodies using the POTELLIGENT Technology. POTELLIGENT Technology involves
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.